Ocugen, Inc. OCGN
0.92 USD -0.04 (-3.86%)
Nov 12, 2026, 12:01 PM EST
0.89 Day range 0.9298
0.691 52-week range 2.73
- YTD
- -31.61%
- 1 year
- -31.10%
News
globenewswire.com Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN MALVERN, Pa. and SYDNEY, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, and…
zacks.com Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises OCGN's Q3 revenues beat estimates. Shares surge 17.4%.
benzinga.com UPDATE: Ocugen Q3 Adj. EPS $(0.06), Inline, Sales $1.951M Beat $1.098M Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.07) per share from the same period…
benzinga.com Ocugen Q3 2026 Earnings Call Transcript Ocugen (NASDAQ:OCGN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time…
benzinga.com Ocugen Q3 EPS $(0.01) Beats $(0.06) Estimate, Sales $1.951M Beat $1.098M Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.06) by 83.33 percent. This is a 85.71 percent increase over losses of $(0.07) per…- benzinga.com Ocugen Executes Licensing Agreement With Roots Pharma And Its Strategic Partner Al-Dhow International For Exclusive Rights To OCU400 For Treatment Of Retinitis Pigmentosa In Middle East And North Africa Region Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapiesExpands access…
benzinga.com Transcript: Ocugen Q2 2026 Earnings Conference Call Ocugen (NASDAQ:OCGN) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts…
benzinga.com Ocugen Receives Bahamas Regulator Provisional Approval For OCU400 Has Been Granted Approval And Priority Designation; The Company Will Supply OCU400 Through An EAP, With Goal Of Treating First RP Patient Within 90 Days Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP)…
benzinga.com What's Happening With Ocugen Stock Thursday? Shares of Ocugen are remaining flat Thursday morning as investors continue to weigh disappointing interim clinical trial data.
benzinga.com HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $9.5 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $10 to $9.5.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…
benzinga.com Ocugen Announces First Patient Dosed In Global Phase 3 Registrational Trial Of OCU410, Modifier Gene Therapy Candidate For GA Secondary To Dry Age-Related Macular Degeneration The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine…
benzinga.com Ocugen Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $1.488M Beat $888.833K Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 40 percent decrease over losses of $(0.05) per…- benzinga.com FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet need The designation could…
benzinga.com Ocugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier Gene Therapy For Retinitis Pigmentosa, In The Middle East And North Africa Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400
benzinga.com Canaccord Genuity Maintains Buy on Ocugen, Lowers Price Target to $11 Canaccord Genuity analyst Whitney Ijem maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $12 to $11.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Full Transcript: Ocugen Q1 2026 Earnings Call
- benzinga.com Ocugen Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $1.533M Beat $540.000K Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 20 percent decrease over losses of $(0.05) per…
benzinga.com GeneDx Holdings, Duolingo, Kosmos Energy And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Dow futures up 100 pts. Shares of GeneDx Holdings (WGS) down 39.2% after cutting FY26 sales guidance. Other stocks falling in pre-market trading.
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Ocugen Plans To Commence $115M Senior Notes Offering Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its intention to offer, subject to market…
- benzinga.com HC Wainwright & Co. Maintains Buy on Ocugen, Raises Price Target to $10 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy and raises the price target from $7 to $10.
benzinga.com Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls Ocugen stock falls after Phase 2 OCU410 data for dry AMD trails interim results, despite lesion reduction.- benzinga.com Ocugen's 12-month Data From Phase 2 ArMaDa trial of OCU410 (AAV5-RORA) For Geographic Atrophy Secondary To Dry Age-related Macular Degeneration Demonstrates Statistically Significant Reduction In Lesion Growth Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22%…
- benzinga.com Canaccord Genuity Initiates Coverage On Ocugen with Buy Rating, Announces Price Target of $12 Canaccord Genuity analyst Whitney Ijem initiates coverage on Ocugen (NASDAQ:OCGN) with a Buy rating and announces Price Target of $12.
benzinga.com Why Is Ocugen Stock Soaring Today? Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $10 price target.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Serve Robotics Posts Upbeat Q4 Results, Joins Auna, Acacia Research And Other Big Stocks Moving Higher On Wednesday Dow falls 200+ points as Serve Robotics Inc (NASDAQ: SERV) shares rise 16.2% on better-than-expected earnings and raised sales guidance.
benzinga.com This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst ratings page. Analysts' thoughts on LGND stock.- benzinga.com Oppenheimer Initiates Coverage On Ocugen with Outperform Rating, Announces Price Target of $10 Oppenheimer analyst Leland Gershell initiates coverage on Ocugen (NASDAQ:OCGN) with a Outperform rating and announces Price Target of $10.
benzinga.com Earnings Summary: Ocugen Q4 - benzinga.com Ocugen Q4 EPS $(0.06), Inline, Sales $(193.000K) Miss $860.000K Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 20 percent decrease over losses of $(0.05) per share from the same period last…
- benzinga.com Earnings Scheduled For March 4, 2026
benzinga.com Examining the Future: Ocugen's Earnings Outlook 
benzinga.com Ocugen Completes Enrollment In Late-Stage Blindness Trial, Eyes FDA Filing In 2026 Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that enrollment is now complete for the OCU400 Phase 3…
benzinga.com Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering Ocugen shares sank sharply Wednesday after the biotech company announces a $22.5 million underwritten offering of common stock.
benzinga.com Ocugen Stock Is Surging Today: What's Driving The Action? Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment.
benzinga.com Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage Ocugen reports early phase 2 data showing its eye gene therapy reduced lesion growth by up to 54%, with no serious safety issues.
benzinga.com OS Therapies Bone Cancer Trial Data Strengthens FDA Case OS Therapies releases trial data supporting FDA approval, U.K. and U.S. timelines, and potential eligibility for a valuable priority review voucher.- benzinga.com Ocugen Announces Preliminary 12-Month Data From Phase 2 ArMaDa Clinical Trial Evaluating OCU410 For GA Secondary To Dry Age-Related Macular Degeneration Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2…
- benzinga.com Ocugen Announces Publication Of Positive Phase 1 Gardian1 Trial Results For OCU410ST, Modifier Gene Therapy For Stargardt Disease, In Peer-Reviewed Journal Nature Eye Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patientsMALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) --…
- benzinga.com Ocugen Q3 Sales $1.752M Beat $550.000K Estimate Ocugen (NASDAQ:OCGN) reported quarterly sales of $1.752 million which beat the analyst consensus estimate of $550.000 thousand by 218.55 percent. This is a 54.23 percent increase over sales of $1.136…
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com Forecasting The Future: 4 Analyst Projections For Ocugen
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Ocugen Shares Are Trading Higher Monday: What's Going On? Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.- benzinga.com Ocugen Strikes $7.5M Licensing Deal Giving Kwangdong Exclusive Korean Rights To Gene Therapy For Blindness Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today executed a licensing agreement with Kwangdong Pharmaceutical,…